Kendzia S, Franke S, Kr xf6 hler T, Golob Schwarzl N, Schweiger C, Toeglhofer A, et al. A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer. Mol Cancer. 2023;22:89 pubmed publisher

Qian B, Wang P, Zhang D, Wu L. m6A modification promotes miR-133a repression during cardiac development and hypertrophy via IGF2BP2. Cell Death Discov. 2021;7:157 pubmed publisher

Kessler S, Laggai S, Barghash A, Schultheiss C, Lederer E, Artl M, et al. IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype. Cell Death Dis. 2015;6:e1894 pubmed publisher

Kessler S, Pokorny J, Zimmer V, Laggai S, Lammert F, Bohle R, et al. IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling. Am J Physiol Gastrointest Liver Physiol. 2013;304:G328-36 pubmed publisher